0.8675  0.007 (0.85%)		12-05 16:00
Open: 0.854 High: 0.9075 Volume: 209,009		Pre. Close: 0.8602 Low: 0.8381 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	1.16	1-year :	1.35
Resists	First :	0.99	Second :	1.15
Pivot price	0.87
Supports	First :	0.73	Second :	0.6
MAs	MA(5) :	0.85	MA(20) :	0.91
	MA(100) :	1.19	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	28.6	D(3) :	27.2
RSI	RSI(14): 44
52-week	High :	4.17	Low :	0.73

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CAPS ] has closed above bottom band by 49.1%. Bollinger Bands are 21.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.91 - 0.91	0.91 - 0.92
Low:	0.83 - 0.83	0.83 - 0.84
Close:	0.86 - 0.87	0.87 - 0.87

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Tue, 02 Dec 2025
Capstone (NASDAQ: CAPS) seals Canadian Stone buy, advancing $100M run-rate goal - Stock Titan

Fri, 28 Nov 2025
Capstone Holding Corp. lowers convertible note conversion price to $0.75 - Investing.com

Tue, 25 Nov 2025
Capstone Therapeutics Approves Reincorporation to Nevada - The Globe and Mail

Tue, 18 Nov 2025
Capstone Holding Corp. SEC 10-Q Report - TradingView

Mon, 17 Nov 2025
Capstone Holding (NASDAQ: CAPS) Adds $26M Revenue, Targets $100M Run-Rate - Stock Titan

Mon, 17 Nov 2025
Capstone Reports Record Q3 Results With 46% EBITDA Growth and New Acquisition Momentum - ACCESS Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Basic Materials
Industry: Construction Materials
Shares Out	8 (M)
Shares Float	5 (M)
Held by Insiders	41.7 (%)
Held by Institutions	0.9 (%)
Shares Short	275 (K)
Shares Short P.Month	268 (K)

EPS	-8.66
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.99
Profit Margin	-12.4 %
Operating Margin	-5.7 %
Return on Assets (ttm)	-3.2 %
Return on Equity (ttm)	-20.3 %
Qtrly Rev. Growth	10.8 %
Gross Profit (p.s.)	1.17
Sales Per Share	5.38
EBITDA (p.s.)	-0.28
Qtrly Earnings Growth	0 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-0.11
PEG Ratio	0
Price to Book value	0.21
Price to Sales	0.16
Price to Cash Flow	-5.73

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.